Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2025)

Caribou Biosciences has reported Cash & Current Investments over the past 6 years, most recently at $139.3 million for Q4 2025.

  • Quarterly Cash & Current Investments fell 33.5% to $139.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.3 million through Dec 2025, down 33.5% year-over-year, with the annual reading at $139.3 million for FY2025, 33.5% down from the prior year.
  • Cash & Current Investments was $139.3 million for Q4 2025 at Caribou Biosciences, down from $147.3 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $435.3 million in Q3 2021 and troughed at $46000.0 in Q2 2021.
  • The 5-year median for Cash & Current Investments is $253.4 million (2022), against an average of $251.0 million.
  • Year-over-year, Cash & Current Investments tumbled 99.86% in 2021 and then surged 738865.22% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $375.8 million in 2021, then plummeted by 34.1% to $247.7 million in 2022, then soared by 32.77% to $328.8 million in 2023, then tumbled by 36.28% to $209.5 million in 2024, then crashed by 33.5% to $139.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Cash & Current Investments are $139.3 million (Q4 2025), $147.3 million (Q3 2025), and $183.9 million (Q2 2025).